Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

20
Rounds Report: Gemphire Enjoyed A Robust Appreciation Backed By Strong Fundamentals

11h seekingalpha
The bioscience market demonstrated a big comeback today following a slumbering Monday. Many equities under our coverage continued to rally and thereby procure more profits for shareholders.
ENTA MDGL GILD GLMD GEMP ICPT IBB XBI

8
Rounds Report: Galmed Rallied Subsequent To The Overweight Rating Of Dr. Elemer Piros

2018-07-15 seekingalpha
The overall bioscience market ended the second week of July with a mixed sentiment. Nevertheless, many equities under our coverage continued to rally and thereby procured more profits.
INFI MDGL GLMD IBB XBI

13
Top Analyst Upgrades and Downgrades: AT&T, BlackRock, Broadcom, Diageo, Kinross Gold, United Rentals, Williams-Sonoma and More

2018-07-13 247wallst
Stocks were looking for direction on Friday, with mixed results in the major equity index futures this Friday the 13th. Investors have had less faith buying the dips in 2018 than in prior years. Many of those investors also have been concerned about how they want their investments positioned ahead of the midterm elections and into international trade concerns and for the longer-term into 2019 and beyond.
WSM GLMD TWX MS.PRE MS.PRF MS.PRG MS.PRA KGC AVGO MS DGE DGE DEO HL.PRB K TWC BLK XLRN MS.PRI T BK MS.PRK URI HL TRI BRCM

15
Rounds Report: The Strong Rally Of Galmed Is Reflective Of Aramchol's Prospects

2018-07-13 seekingalpha
The overall bioscience market traded with the strong confidence going into the weekend. Many equities under our coverage continue to rally and thereby procured increasing profits for shareholders.
TSRO OPK GLMD BRLI IBB XBI PFE

22
Gemphire: Is There More To This Strong Grower?

2018-07-13 seekingalpha
Gemcabene is being innovated in various franchises including nonalcoholic fatty liver disease (“NAFLD”)/nonalcoholic steatohepatitis (“NASH”) and dyslipidemias.
ENTA MDGL GILD GLMD GEMP ICPT

49
Innovate: Are There Further Upsides From This Robust Grower?

2018-07-13 seekingalpha
As a momentum stock, Innovate’s shares gained over 100% in just two weeks. A fundamental analysis to reveal whether there are further upsides.
ENTA MDGL GILD INNT GLMD ICPT

7
Galmed Pharmaceuticals: Strong Fundamentals Powering A NASH Innovator

2018-07-06 seekingalpha
Galmed is advancing its novel molecule (Aramchol) for the management of nonalcoholic steatohepatitis. Aramchol demonstrated strong preclinical and clinical data thus far.
ENTA MDGL GILD GLMD ICPT

56
Biotech: Take It On The Run

2018-07-05 seekingalpha
Jonathan Faison, author of ROTY on Marketplace, says his approach to biotech investing offers a framework for disciplined decision-making.
BLCM SLDB GLMD LOXO INCY ARQL NTEC KDMN SRPT MGTX AQXP 4508 IFRX MTZXF ARGX GWPH MTZPY NVS CTMX GWP

128
Gemphire's Positive Phase 2b Results Reignites The NASH Market Yet Again

2018-07-02 seekingalpha
Gemphire Therapeutics obtains positive phase 2b results in treating patients with severe Hypertriglyceridemia (high levels of triglycerides) using its drug gemcabene.
MDGL VKTXW HGRL GILD CNAT GLMD GEMP ICPT VKTX

1
GLMD / Galmed Pharmaceuticals Ltd. / 683 Capital Management, LLC - JUNE 19, 2018 (Passive Investment)

2018-06-22 sec.gov
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
GLMD

2
GLMD / Galmed Pharmaceuticals Ltd. / 683 Capital Management, LLC - JUNE 19, 2018 (Passive Investment)

2018-06-22 sec.gov
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
GLMD

0
GLMD / Galmed Pharmaceuticals Ltd. PROSPECUTS SUPPLEMENT (Prospectus)

2018-06-21 sec.gov
tv496777-424b5 - none - 5.02949s TABLE OF CONTENTS
GLMD

3
Madrigal, Galmed, And Oramed, A NASH Love Triangle

2018-06-18 seekingalpha
Galmed reported positive results for its NASH treatment Aramchol in a Phase II trial last week.
GLMD

4
GLMD / Galmed Pharmaceuticals Ltd. FREE WRITING PROSPECTUS

2018-06-18 sec.gov
Filed Pursuant to Rule 433 Registration No. 333-223923 Issuer Free Writing Prospectus dated June 18, 2018
GLMD

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: M47238106